Can you feel the ground moving beneath your feet? Shares of Facebook (NASDAQ:FB) soared nearly …

Advanced Micro Devices, Inc. (NASDAQ:AMD) just riled up Wall Street with enticing first-quarter earnings results, sending …

Facebook (NASDAQ:FB) reported its first-quarter financial results, and investors must have liked what they heard …

It’s a very rewarding trading day for investors in Dare Bioscience (NASDAQ:DARE) with shares up …

Tigress’ Ivan Feinseth spotlights any share weakness as an enticing opportunity to buy SQ stock.

Baird’s Colin Sebastian is reassured to see solid key metrics that led to Twitter’s outclass on Q1 expectations- but here’s why he remains sidelined;

Wedbush’s Michael Pachter believes the overall impact from Cambridge Analytica privacy-related scrutiny will be “minimal” in Q1 results.

Credit Suisse’s John Pitzer spotlights that while crypto GPU revenue is “waning” in steam, in the short-term up to $200 million in upside could be waiting in the wings.

RBC Capital’s Mark Mahaney predicts the Street’s expectations for Twitter are “reasonable” ahead of Q1 results- from the sidelines.

Mizuho’s Vijay Rakesh chimes in on what he anticipates for the 2018 DRAM and NAND flash memory backdrop facing MU after the company’s chip competitor Hynix’s Q1 earnings release.

Stifel’s Scott Devitt remains apprehensive on FB in his Q1 earnings preview, wary of sluggish revenue growth and business implications in a post-Cambridge Analytica era.

Montana Skeptic is a well known Tesla (NASDAQ:TSLA) skeptic and short seller who writes frequently …

Nasdaq-halted Longfin (NASDAQ:LFIN) is now in an ‘Event of Default’ with respect to its $52.7M convertible …

It’s been a rough few weeks for social media giant Facebook (NASDAQ:FB). As we discussed just …

Last week, vTv Therapeutics Inc (NASDAQ:VTVT) announced that azeliragon, the company’s RAGE inhibitor in development …

What does the future hold for Tesla (NASDAQ:TSLA) and Twitter (NYSE:TWTR)? Sell-side analysts from Bernstein and Morgan …

Yesterday, Merck (NYSE:MRK) reported data from Keytruda in combo with chemotherapy for patients with non-small …